Germany-based global drugmaker Bayer and Rockland, Mass.-based EMD Serono will limit drug discounts ensured through the 340B program to covered entities and not include contract pharmacies. The changes are effective March 1, Bayer and EMD Serono said in letters
340B Health said these are the 20th and 21st drugmakers to narrow discounted drugs to 340B hospitals, which care for an uninsured community. The others are AbbVie, Amgen, AstraZeneca, Bausch Health, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Exelixis, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics, the organization said.
The news comes two days after an appeals court ruled that Sanofi, AstraZeneca and Novo Nordisk can deny the drug discounts to contract pharmacies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
